To provide a new aryltetrahydropyridine derivative useful for the treatment or prevention of diseases supposed to be concerned with corticotropin releasing factor(CRF) such as depression, anxiety and Alzheimer's disease.
The objective compound is expressed by formula I [Ar is phenyl, thienyl or the like; R1 is H, a lower alkyl or the like; X1 to X3 are each H, a halogen, a lower alkyl, a lower alkylthio or the like; Y1 is N or the like; Y2-Y3 is N=N, N=C(R3) (R3 is H or a lower alkyl) or the like], e.g. 6-[4-(4- chlorophenyl)-1,2,3,6-tetrahydropyridin-1-yl]-2-methyl-9-(2-methylthio-4- isopropylphenyl)purine. The compound of formula I can be produced e.g. by reacting a compound of formula II with a compound of formula III in an inert solvent (e.g. acetonitrile) in the presence of a base (e.g. triethylamine).
KUMAGAI TOSHIHITO
OKUBO TAKETOSHI
KATAOKA HIROMI
TOMIZAWA KAZUYUKI
Next Patent: HYDRATED MAGNESIUM HYDROGEN CITRATE AND ITS PRODUCTION